Breaking News Headlines Today | Ground News

Holiday Sale — Get 40% off Vantage for yourself or as a gift

Labiotech.eu image

News from Labiotech.eu

The Ground News media bias check for Labiotech.eu is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and AllSides.

Is Labiotech.eu credible or reliable? Our Factuality score answers both of those questions. When it comes to Labiotech.eu, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about Labiotech.eu

Where is Labiotech.eu located?Labiotech.eu's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Labiotech.eu News

JASCAYD® (Nerandomilast) Receives First Regulatory Approval for Progressive Pulmonary Fibrosis in China

JASCAYD® (Nerandomilast) Receives First Regulatory Approval for Progressive Pulmonary Fibrosis in China

China’s National Medical Products Administration has approved JASCAYD® as the first new treatment for adults with progressive pulmonary fibrosis in more than five years, marking a breakthrough for millions affected by the life-threatening lung condition. [Boehringer Ingelheim] Press Release See the Story

Pharma Sector Records Higher Deal Value in November 2025

Pharma Sector Records Higher Deal Value in November 2025

GlobalData has reported deal activity trends for the pharmaceuticals industry in November 2025. According to the report, deal value increased by 274.8 per cent in November 2025 compared to November 2024. The healthcare industry recorded 53 deals worth USD 38.7 billion, compared to the 12-month average (November 2024 to October 2025) of 90 deals worth USD 18.1 billion. The largest announced transactions in November 2025, as stated in the report, …See the Story

Vandria Reports First Human Data for Mitophagy-Based Alzheimer’s Drug VNA-318

Alzheimer's Disease · Germany

Vandria Reports First Human Data for Mitophagy-Based Alzheimer’s Drug VNA-318

Vandria has announced the first-in-human data for its A […] The post Vandria Reports First Human Data for Mitophagy-Based Alzheimer’s Drug VNA-318 first appeared on GeneOnline News. The post Vandria Reports First Human Data for Mitophagy-Based Alzheimer’s Drug VNA-318 appeared first on GeneOnline News.See the Story

Breaking News Topics Related to Labiotech.eu